Veritas Pharma Inc. has appointed Linda Sampson as a Director of the Company.
Dr. Lui Franciosi commented: “We are very pleased to welcome Ms. Sampson to the board of directors of Veritas Pharma and to have someone with Linda’s experience joining the board of Veritas Pharma. Her intimate knowledge of the emerging cannabis industry and her experience in the equity market will be a significant asset as Veritas Pharma continues to advance its business objectives.”
The company also wishes to announce the resignation of director Len Werden. The board and management would like to sincerely thank Mr. Werden for his contribution to the development of Veritas and wish him well in his future endeavours.
Ms. Sampson brings a dynamic energy, a wealth of talent and a multilayered business expertise to the company. She is a business start-up professional, with a history of ground-up to successful ventures. An accomplished sales professional, marketer, designer and developer with international experience, she brings superior business branding skills and internal administration expertise to Veritas. Ms. Sampson is currently president of Marapharm Ventures Inc. Marapharm is a developmental-stage publicly traded medical marijuana company with operations based in British Columbia, and Nevada and Washington in the United States.
Ms. Sampson commented: “I am impressed with the medical research being conducted by Veritas and its associates. I look forward to working the Cannevert group of scientists to help monetize their intellectual property which is currently being developed. I strongly feel that there are several synergies between Veritas and Marapharm which should result in a win-win for the shareholders of each”
The company is also pleased to announce that it is issuing 800,000 stock options at 45 cents with a one-year term to directors, management and consultants.
Veritas Pharma is a pharmaceutical and IP development company, which, through Cannevert Therapeutics Ltd., is advancing the science behind medical cannabis. It is the company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and post traumatic stress disorder, solving the critical need for clinical data to support medical marijuana claims.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
Read Next
